Boston, MA -- (SBWIRE) -- 07/07/2017 -- Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Get More Details on this Report and a Full Table of Contents at Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2017

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 2, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myeloproliferative Disorders, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atopic Dermatitis, Myelofibrosis, Asthma, Auto Inflammatory Disease, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Leukemias, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Anaplastic Astrocytoma, B-Cell Leukemia, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Dermatitis, Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoma, Multiple Sclerosis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Failure, Respiratory Tract Inflammatory Disorders, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Thalassemia, Thrombocythemia Myelofibrosis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

-The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

Companies Mentioned in this Report: Aerie Pharmaceuticals Inc, Aptose Biosciences Inc, AstraZeneca Plc, Bristol-Myers Squibb Company, Celon Pharma SA, CTI BioPharma Corp, Eli Lilly and Company, Genentech Inc, Incyte Corp, Japan Tobacco Inc, Nerviano Medical Sciences Srl, Nippon Shinyaku Co Ltd, Novartis AG, Simcere Pharmaceutical Group, Theravance Biopharma Inc, Tragara Pharmaceuticals Inc, Vectura Group Plc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Tyrosine Protein Kinase SYK - Pipeline Review, H1 2017
-Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2017
-Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017
-High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2017
-Tyrosine Protein Kinase ITK/TSK - Pipeline Review, H1 2017